US12612449B2 HIV-1 Antibodies - University of Melbourne
Summary
The USPTO granted patent US12612449B2 to The University of Melbourne on April 28, 2026. The patent, classified under CPC C07K 16/081 (filed June 10, 2021, Application No. 18007859), covers antigen binding sites, antibodies and fragments thereof, as well as compositions, kits and uses thereof for the treatment, attenuation and/or prevention of HIV-1. The patent contains 10 claims.
“The invention relates to antigen binding sites, antibodies and fragments thereof, as well as compositions, kits and uses thereof for the treatment, attenuation and/or prevention of human immunodeficiency virus type 1 (HIV-1).”
About this source
Granted patents in USPTO classification C07K, covering peptides, proteins, antibodies, and related biological molecules. Around 160 grants a month, each with the patent number, title, applicant, inventor names, and full abstract. Unlike published applications (which reveal in-progress research), grants are enforceable rights and signal what a company can now litigate or license. Watch this if you run an antibody or protein biologics program, advise on patent portfolio strategy for biologics companies, scout for licensing opportunities on recently granted claims, or track which research institutions are converting their early peptide work into issued patents.
What changed
The USPTO issued US Patent US12612449B2 to The University of Melbourne for HIV-1 antibodies, classified under CPC C07K 16/081. The patent covers antigen binding sites, antibodies, fragments thereof, and compositions for treating, attenuating, or preventing HIV-1 infection. Inventors are Damian Purcell and Behnaz Heydarchi.
Patent holders and biotechnology researchers working on HIV-1 therapeutics should review the claims to assess potential overlap with their development programs. This is a routine patent grant creating intellectual property rights with no direct compliance obligations for third parties.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HIV-1 antibodies
Grant US12612449B2 Kind: B2 Apr 28, 2026
Assignee
The University of Melbourne
Inventors
Damian Purcell, Behnaz Heydarchi
Abstract
The invention relates to antigen binding sites, antibodies and fragments thereof, as well as compositions, kits and uses thereof for the treatment, attenuation and/or prevention of human immunodeficiency virus type 1 (HIV-1).
CPC Classifications
C07K 16/081
Filing Date
2021-06-10
Application No.
18007859
Claims
10
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.